10-Q: Mural Oncology Q3: Acquisition Pending, R&D Halted

Mural Oncology plc reports Q3 2025 results amidst a pending acquisition by XOMA Royalty Corporation, following the discontinuation of all clinical and preclinical development programs.

Summary

• Mural Oncology plc has discontinued all clinical development of its lead product candidate, nemvaleukin alfa, due to failed Phase 3 ARTISTRY-7 and Phase 2 ARTISTRY-6 trials.
• All preclinical development activities were ceased on June 3, 2025.
• The company entered into a Transaction Agreement with XOMA Royalty Corporation on August 20, 2025, for an acquisition, which shareholders approved on October 24, 2025, and is expected to close in Q4 2025.
• Shareholders are entitled to a base cash price of $2.035 per share, with a potential additional cash amount of up to $0.205 per share based on closing net cash.
• A workforce reduction of approximately 90% (104 positions) was completed by the end of Q2 2025.
• The company reported a net loss of $3.7 million for the three months ended September 30, 2025, significantly lower than $31.8 million for the same period in 2024, primarily due to the cessation of R&D activities and a $4.8 million credit from a change in estimate for ARTISTRY-6 trial costs.
• For the nine months ended September 30, 2025, the net loss was $84.8 million, compared to $94.2 million for the same period in 2024.
• Cash and cash equivalents decreased to $58.9 million as of September 30, 2025, from $115.5 million at December 31, 2024.
• The company has concluded there is substantial doubt about its ability to continue as a going concern if the acquisition or an alternative strategic transaction is not consummated.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the complete failure of the lead product candidate in late-stage clinical trials, the cessation of all R&D and preclinical programs, a 90% workforce reduction, and management's explicit statement of substantial doubt about the company's ability to continue as a going concern. The pending acquisition, while providing an exit, is a consequence of these failures rather than a positive strategic growth initiative.

Positives

• Shareholders approved the acquisition by XOMA Royalty Corporation on October 24, 2025, providing a clear exit strategy and defined cash consideration.
• The acquisition is expected to close during the fourth quarter of 2025, offering a timely resolution for shareholders.
• Net loss for the three months ended September 30, 2025, significantly decreased to $3.7 million from $31.8 million in the prior year, largely due to the cessation of R&D activities and a $4.8 million credit from a change in estimate for ARTISTRY-6 trial costs.
• The company believes it has sufficient cash to fund operations for the next twelve months from the report date, following the discontinuation of clinical development and workforce reduction.

Negatives

• All clinical development of nemvaleukin alfa, the company's lead product candidate, has been discontinued due to failed Phase 3 ARTISTRY-7 and Phase 2 ARTISTRY-6 trials.
• All preclinical development programs were ceased on June 3, 2025, indicating a complete halt to internal pipeline development.
• The company has incurred significant operating losses and negative cash flows from operations since its inception and expects this to continue for the foreseeable future.
• There is substantial doubt about the company's ability to continue as a going concern if the pending acquisition or an alternative strategic transaction is not consummated.
• A workforce reduction of approximately 90% (104 positions) was implemented, reflecting the severe contraction of operations.
• Cash and cash equivalents declined significantly to $58.9 million as of September 30, 2025, from $115.5 million at December 31, 2024.
• Restructuring and impairment charges totaled $17.5 million for the nine months ended September 30, 2025, including $9.5 million in employee-related costs and $5.5 million in impairment charges.
• The company has no products approved for commercial sale and has not generated any revenue from product sales.
• Increased general and administrative expenses for the three and nine months ended September 30, 2025, due to legal expenses associated with corporate activities and higher allocated facilities costs.

Risks

• Failure to consummate the acquisition by XOMA Royalty Corporation or to identify and implement any other strategic transaction could have negative consequences.
• Shareholders cannot be sure of the exact amount of consideration they will receive in the acquisition, as the additional cash amount of up to $0.205 per share is contingent on closing net cash exceeding an estimated $36.2 million.
• Provisions in the transaction agreement may discourage other companies from attempting to enter into a strategic transaction for greater consideration.
• If the acquisition or an alternative strategic transaction is not consummated, the board of directors may decide to pursue a dissolution and liquidation, which could result in shareholders losing all or a significant portion of their investment.
• The corporate restructuring and associated headcount reduction may not result in anticipated savings, could incur greater costs than expected, and could disrupt business operations, including employee morale and retention.
• The company's limited operating history as a standalone entity makes valuing the business and predicting its prospects challenging.
• Significant losses are anticipated to continue for the foreseeable future, and the company may never generate revenue or achieve profitability.
• Additional funding would be required to advance any product candidates if development were to resume, which may not be available on acceptable terms or at all.
• Biopharmaceutical product development is a lengthy, expensive, and uncertain process, with a high risk of failure, as demonstrated by the nemvaleukin trials.
• The company could be required to indemnify the Former Parent (Alkermes plc) for material taxes if the Separation and Distribution do not qualify as tax-free for U.S. federal income tax purposes.
• As an emerging growth company and smaller reporting company, reduced disclosure requirements may make ordinary shares less attractive to investors.
• The price of ordinary shares is subject to volatility related or unrelated to operations and/or the prospect of consummating the acquisition.
• Irish law, under which the company is incorporated, differs from U.S. laws and might afford less protection to holders of securities, and takeover offers are subject to Irish Takeover Rules.
• The ability to consummate the acquisition or an alternative strategic transaction depends on retaining employees required for the transaction.
• Adverse developments affecting the financial services industry could adversely affect business operations and financial condition.
• Manufacturing of biological products is complex, and the company relies on single-source third-party manufacturers, exposing it to risks of delays, quality issues, or supply interruptions.
• Developing product candidates in combination with third-party drugs entails risks related to control over safety, supply, and regulatory status of those drugs.
• Reliance on third-party collaborators or licensors for R&D and commercialization carries risks of limited control and potential failure to achieve expected benefits.
• Inability to obtain or maintain adequate patent protection or enforce intellectual property rights globally could harm the business.
• Claims of patent infringement or trade secret misappropriation could result in costly litigation.
• Failure to comply with obligations under license, collaboration, or other agreements could lead to damages or loss of intellectual property rights.
• Unfavorable global economic or political conditions, including geopolitical tensions and trade wars, could adversely affect the business.
• Loss of key management personnel could impair the business strategy.
• Relationships with healthcare providers and payors are subject to anti-kickback, fraud and abuse, and other healthcare laws and regulations, which could lead to penalties.
• Subject to U.S. and non-U.S. anti-corruption, anti-money laundering, export control, sanctions, and other trade laws, with potential for serious consequences for violations.
• Adversely affected by significant administrative law cases decided by the U.S. Supreme Court in 2024, other ongoing litigation involving the FDA, and changes in the executive branch of the federal government.
• Difficulty in estimating potential market sizes for product candidates, leading to potentially smaller actual markets.
• Uncertainty regarding receipt or benefits of Fast Track, Priority Review, Breakthrough Therapy, ILAP, or PRIME designations.
• Uncertainty regarding obtaining or maintaining Orphan Drug designations and associated market exclusivity.
• Regulatory approval in one jurisdiction does not guarantee approval in others.
• Failure of any approved product candidate to achieve market acceptance by physicians, patients, and payors.
• No history of commercializing products and no established commercialization operations.
• Risk of expending limited resources on less profitable product candidates or indications.
• Unfavorable insurance coverage, inadequate reimbursement levels, and cost-effective pricing policies with third-party payors.
• Ongoing regulatory obligations and continued regulatory review, with potential for significant additional expense and penalties for non-compliance.
• FDA, EMA, and other regulatory authorities actively enforce laws prohibiting the promotion of off-label uses.
• Inadequate funding for regulatory agencies could hinder their ability to perform normal business functions.
• Computer systems, or those of third-party collaborators, service providers, contractors, or consultants, may suffer security breaches or fail.
• May not achieve some or all of the expected benefits of the Separation from Alkermes plc.
• Agreements with the Former Parent may not reflect terms that would have resulted from negotiations with unaffiliated third parties.
• Indemnification obligations to the Former Parent under the tax matters agreement are not limited in amount or subject to any cap.
• Restrictions under the tax matters agreement may limit the ability to engage in attractive strategic or capital-raising transactions following the Separation.
• The company believes it will be treated as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes for the period covered by this report, which could have material adverse tax consequences for U.S. holders.
• Increased costs and management time due to operating as a public company.
• An active trading market for ordinary shares may not develop or be sustained.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Transfers of ordinary shares may be subject to Irish stamp duty.
• Ability to obtain financing may be limited by future financing arrangements and provisions of Irish law.
• No guarantee that distributable reserves needed to pay dividends will be created.
• If a quorum is not present at a general meeting, decisions may be taken at an adjourned meeting by those shareholders in attendance, irrespective of their number.

Future Outlook

The company expects its acquisition by XOMA Royalty Corporation to close during the fourth quarter of 2025. While existing cash is believed to be sufficient for the next twelve months following the discontinuation of all development and workforce reduction, there is substantial doubt about the company's ability to continue as a going concern if the acquisition or an alternative strategic transaction is not consummated. The company is also restricted from certain strategic or capital-raising transactions for a four-year period due to a tax matters agreement with its Former Parent.

Management Comments

• "Although following discontinuation of clinical development of nemvaleukin and the related reduction in force, we believe we will have sufficient cash to fund operations for the next twelve months from the date this Quarterly Report is issued, there can be no assurance that the Acquisition or any alternative strategic transaction will be completed and our board of directors may decide to pursue a dissolution and liquidation, amongst other alternatives, if the Acquisition or an alternative strategic transaction is not consummated."
• "Due to the inherent uncertainty in the timing and cost of potential strategic alternatives, including impact on our cash consumption, we have concluded that as of the date of this Quarterly Report there is substantial doubt about our ability to continue as a going concern."
• "Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report."
• "Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report."

Industry Context

Mural Oncology operates in the highly competitive and high-risk biopharmaceutical oncology industry. The discontinuation of its lead product candidate after failed Phase 3 trials is a common, yet severe, setback in drug development, often leading to strategic re-evaluations or acquisitions. The pending acquisition by XOMA Royalty Corporation reflects a trend for biotech companies with failed pipelines to seek M&A as an exit strategy to maximize shareholder value or avoid liquidation. The industry continues to face significant regulatory hurdles, lengthy and expensive development processes, and intense competition, alongside increasing scrutiny on drug pricing and data privacy regulations.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. The company is in a wind-down/acquisition phase after failed clinical trials, making direct performance comparisons to industry standards difficult and not provided within the scope of this filing.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its financial condition, results of operations, or cash flows.
• There is a risk of becoming involved in securities litigation or shareholder derivative litigation in connection with the acquisition, which could divert management attention and incur costs.

Related Party Transactions

• Receivable from Former Parent (Alkermes plc) of $51,000 as of September 30, 2025.
• The Former Parent is jointly and severally liable with the company for, and continues to guarantee, all obligations under the Winter Street Lease.
• The company entered into various agreements with the Former Parent (separation, tax matters, employee matters, lease assumption, transition services) in connection with the Separation.

Stakeholder Impact

• Shareholders: Will receive cash consideration from the pending acquisition, but the amount is uncertain and capped. Face the risk of losing all or a significant portion of their investment if the acquisition fails and liquidation occurs.
• Employees: Experienced a 90% workforce reduction, leading to job losses. Remaining employees may face reduced morale and potential attrition.
• Creditors: The company has obligations that would need to be paid in a liquidation scenario, with uncertainty regarding timing and sufficiency of assets.
• Regulatory Authorities: The company continues to be subject to ongoing regulatory compliance requirements, particularly concerning financial reporting and corporate governance.

Next Steps

• Closing of the acquisition by XOMA Royalty Corporation during the fourth quarter of 2025.
• If the acquisition is not consummated, the board of directors may decide to pursue a dissolution and liquidation.
• Evaluating the impact of ASU No. 2023-09 (Income Taxes) and ASU No. 2024-03 (Income Statement Expenses) on consolidated financial statements and disclosures.

Key Dates

Recommendation

The company is in the advanced stages of an acquisition by XOMA Royalty Corporation, with shareholder approval already secured and an expected closing in Q4 2025. This transaction provides a defined cash exit for existing shareholders. Given the complete cessation of all R&D activities, the significant workforce reduction, and the explicit 'going concern' doubt, the company's standalone operational value is effectively zero. Therefore, the primary investment consideration is the successful completion of the acquisition at the stated terms. A 'Hold' recommendation is appropriate as the acquisition price is largely determined, and significant upside or downside from current levels is limited unless the acquisition unexpectedly fails or the final net cash calculation differs substantially from expectations, which would then warrant a re-evaluation.

Keywords

Mural Oncology, XOMA Royalty Corporation, Acquisition, Biotechnology, Oncology, Immunotherapy, Nemvaleukin alfa, Clinical trials, ARTISTRY-7, ARTISTRY-6, Drug development, Strategic alternatives, Going concern, SEC filing, 10-Q, Financial results, Workforce reduction, Corporate governance, Risk factors